Professor Josh Davis
Senior principal research fellow
Qualifications:
PhD, Charles Darwin University, 2011
Bachelor of Medicine and Bachelor of Surgery, University of Sydney, 1994
Diploma of Tropical Medicine and Hygiene, University of Liverpool (UK), 1998
Graduate Diploma of Population Health, University of Newcastle, 2008
Fellow of the Royal Australasian College of Physicians in Infectious Diseases, 2005
Approved level of HDR supervision at Charles Darwin University:
Principal Supervisor for PhD
Location:
Biography:
Josh is a clinician researcher, and divides his time between clinical work as an Infectious Diseases physician in Newcastle, and research work as a principal research fellow based at Menzies.
He completed his clinical infectious diseases training in 2004, and then worked on a PhD from 2007-2010 on the epidemiology, pathophysiology and adjunctive treatment of sepsis in the Top End of the Northern Territory (NT).
His main research interests are clinical trials in the management of severe infections, epidemiology of severe bacterial infections, and the clinical and molecular epidemiology of viral hepatitis.
Josh is the clinical lead for viral hepatitis for the Hunter New England local health district in NSW, and the clinical lead for the COVID-19 expert reference group for the Hunter New England local health district.
In 2018, Josh was awarded a research excellence award from the NHMRC for the top ranked career development fellowship, and he is a chief investigator on several ongoing large multinational RCTs including SNAP (adaptive platform trial assessing multiple treatments for Staph aureus bacteraemia), ASCOT (adaptive platform trial of therapeutic agents for COVID-19), BLING3 (RCT of continuous infusion versus bolus dosing of antibiotics in ICU) and SUDDICU (Cluster cross-over RCT of selective digestive tract decontamination in ICU). He also established and is the co-lead of the Menzies Viral Hepatitis Research Program.
Research Themes
- ASCOT (adaptive platform trial of therapeutic agents for COVID-19)
- SUDDICU (Cluster cross-over RCT of selective digestive tract decontamination in ICU)
- BLING3 (RCT of continuous infusion versus bolus dosing of antibiotics in ICU)
- AC-DC (Acinetobacter colonisation in Darwin and NT Communities)
- HBV-PAST
- SNAP (adaptive platform trial assessing multiple treatments for Staph aureus bacteraemia)
- CHARM (molecular epidemiology of Hepatitis B virus (HBV) in the Top End)
- ELEPHANT (epidemiology of liver cancer); developing an Ipad-based educational resource about HBV in Yolngu and English with partners from Galiwinku
https://scholar.google.com/citations?user=F4soxgEAAAAJ&hl=en
Over 120 peer-reviewed published papers, with an h-index of 30 and over 4,600 citations.
- Davis, J.S., McMillan, M., Swaminathan, A., Kelly, J.A., Piera, K.E, Baird, R.W., Currie, B.J., Anstey, N.M. (2014). A 16-year prospective study of community-onset bacteremic Acinetobacter pneumonia: low mortality with appropriate initial empirical antibiotic protocols. Chest, 146(4), 1038-1045.
- Parker, C., Tong, S.Y.C., Dempsey, K., Condon, J., Sharma, S.K., Chen, J.W.C., Sievert, W., Davis, J.S. (2014). Hepatocellular carcinoma in Australia's Northern Territory: high incidence and poor outcome. Medical Journal of Australia, 201(8), 470-474.
- Tong, S.Y.C., Davis, J.S., Eichenberger, E., Holland, T.L., Fowler, V.G. (2015). Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clinical microbiology reviews, 28(3), 603-661.
- Dulhunty, J.M., Roberts, J.A., Davis, J.S., Webb, S.A., Bellomo, R., Gomersall, C., et al. (2015). A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. American Journal of Respiratory and Critical Care Medicine, 192(11), 1298-1305.
- Davis, J.S., Mackrow, C., Binks, P., Fletcher, W., Dettwiller, P., Marshall, C., Day, J., Pratt, W., Tong, S.Y.C. (2015). A double-blind randomized controlled trial of ibuprofen compared to placebo for uncomplicated cellulitis of the upper or lower limb. Clinical microbiology and infection, 23(4), 242-246.
- Davies, J., Li, S.Q., Tong, S.Y., Baird, R.W., Beaman, M., Higgins, G., Cowie, B.C., Condon, J.R., Davis, J.S. (2017). Establishing contemporary trends in hepatitis B sero-epidemiology in an Indigenous population. PloS one, 12(9).
- Davis, J.S., Turnidge, J., Tong, S.Y.C. (2018). A large retrospective cohort study of cefazolin compared with flucloxacillin for methicillin-susceptible Staphylococcus aureus bacteraemia. International journal of antimicrobial agents, 52(2), 297-300.
- Yuen, L.K.W., Littlejohn, M., Duchêne, S., Edwards, R., Bukulatjpi, S., Binks, P., Jackson, K., Davies, J., Davis, J.S., Tong, S.Y.C. (2019). Tracing ancient human migrations into Sahul using Hepatitis B Virus genomes. Molecular biology and evolution, 36(5), 942-954.
- Meumann, E.M, Anstey, N.M., Currie, B.J., Piera, K.A., Kenyon, J.J., Hall, R.M., Davis, J.S., Sarovich, D.S. (2019). Genomic epidemiology of severe community-onset Acinetobacter baumannii infection. Microbial genomics, 5(3), 1038-45.
- Davies, J., Smith, E.L., Littlejohn, M., Edwards, R., Sozzi, V., Jackson, K., McGuire, K., Binks, P., Cowie, B.C., Locarnini, S. (2019). Towards Genotype-Specific Care for Chronic Hepatitis B: The First 6 Years Follow Up From the CHARM Cohort Study. Open Forum Infectious Diseases, 6(11), ofz469.
- Sullivan, R.P., Davies, J., Binks, P., Dhurrkay, R.G., Gurruwiwi, G.G., Bukulatjpi, S.M., McKinnon, M., Hosking, K., Littlejohn, M., Jackson, K. (2019). Point of care and oral fluid hepatitis B testing in remote Indigenous communities of northern Australia. Journal of viral hepatitis.
- Davis, J.S., Young, M., Marshall, C., Tate-Baker, J., Madison, M., Sharma, S., Silva, C., Jones, T., Davies, J. (2020). Minimal compared with standard monitoring during sofosbuvir-based hepatitis C treatment: a randomized controlled trial. Open Forum Infectious Diseases, 7(2), ofaa022.
- Tong, S.Y.C., Lye, D.C., Yahav, D., Sud, A., Robinson, J.O., Nelson, J., Archuleta, S., Roberts, M.A., Cass, A., Paterson, D.L. (2013). Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial. Jama, 323(6), 527-537.
.PNG&w=123&h=126)
.jpg&w=123&h=126)
